Stockreport

CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient with ...

CERo Therapeutics Holdings, Inc.  (CERO) 
PDF Company to host analyst call at 5:00pm ET today to discuss progress to date and expansion of clinical trial SOUTH SAN FRANCISCO, Calif, Jan. 07, 2026 (GLOBE NEWSWIRE [Read more]